Novo Nordisk Finds a Few Bright Spots as Its Pipeline Takes Centre Stage
Published on 06/22/2026 at 22:27 | Redaktion boerse-global.de
Novo Nordisk is trying to turn the spotlight away from weaker near-term trading and toward what comes next. A mix of regulatory progress, fresh trial data and steady share buybacks has given the Danish drugmaker a run of support, even as the core business still faces heavy price pressure in the US and a softer start to the year.
On Monday, the stock rose 3.29 percent to 40.18 Euro, extending its rebound from the spring low to roughly 33 percent. In a separate move, it gained around 2.4 percent to 39.82 Euro and was up a little more than five percent for the week, though it still sat about 35 percent below the 52-week high of 61.20 Euro from July 2025 and remained down by nearly eleven percent for the year.
The most immediate catalyst came from the UK, where the MHRA approved the oral Wegovy tablet on 11 June 2026. That made Britain the first European country to clear the treatment and the third regulator worldwide, after the FDA and the authorities in the United Arab Emirates, to license it. The tablet is approved alongside diet and exercise for adults with obesity, defined as BMI ? 30, or overweight with BMI ? 27 plus at least one weight-related comorbidity. A NICE review would be needed before any NHS reimbursement, and that is not expected in the near term.
The US rollout is already showing scale. Novo Nordisk says Wegovy has generated more than three million prescriptions in a little more than five months, making it one of the strongest launches by volume in the history of the US pharmaceutical industry. The oral version is also broadening the market, with about 80 percent of users taking such a treatment for the first time.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Investor attention is not fixed on Wegovy alone. CagriSema has emerged as another key asset, with Novo Nordisk presenting encouraging data at the ADA Congress 2026 in New Orleans. The REIMAGINE studies 1 to 3 all met their primary endpoint in adults with type-2 diabetes, delivering significant improvements in blood sugar, measured by HbA1c, and in body weight. The findings were published simultaneously in the Lancet and Lancet Diabetes & Endocrinology.
Novo Nordisk filed for FDA approval of CagriSema for weight loss in December 2025, and a decision is due in the fourth quarter of 2026. The company had already highlighted at a major diabetes congress that the drug lowered long-term blood sugar by 1.91 percent and achieved all primary study goals. If the regulator signs off, launch could follow in early 2027. In the meantime, the new diabetes results widen the case for the drug ahead of the FDA ruling.
Zenagamtide is also moving deeper into the pipeline. Novo Nordisk has launched a broad clinical programme around the compound, with the first two studies running for 84 weeks and focusing on obesity. Other trials will look at related conditions including sleep apnoea and knee osteoarthritis, while another study will assess the durability of weight loss over the long term. Early data were strong: at the highest dose, body weight fell by 14.6 percent and long-term blood sugar declined markedly. A further study in type-2 diabetes is set to begin in the second half of 2026.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
That future-facing push is happening against a difficult operating backdrop. In the first quarter, adjusted sales fell four percent, hurt by lower US selling prices, and management expects a significant currency-adjusted revenue decline for the full year. Even so, Novo Nordisk has kept returning cash to shareholders. Its buyback programme, launched in February 2026 with a total size of up to 15 billion Danish kroner, is running under EU safe-harbour rules through February 2027. In the week of 8 to 12 June, the company repurchased 1.125 million B shares. By mid-June, it had bought back nearly 20 million shares, and since the start of the programme it has spent almost 5.3 billion kroner. The treasury stock now stands at about 37 million B shares, or 0.8 percent of share capital.
For now, Novo Nordisk’s message to the market is clear: the present is messy, but the pipeline is busy. With the FDA’s CagriSema decision due in the fourth quarter and the broader Zenagamtide programme gathering pace, the stock’s recovery will depend on whether those experimental wins can keep turning into commercial ones.
Ad
Novo Nordisk Stock: New Analysis - 22 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
